human papillomavirus vaccination recommendations, 506–507

influenza vaccination recommendations, 295–296

meningococcal vaccination recommendations, 601

MMR vaccination recommendations, 108, 242

varicella vaccination recommendations, 242

Age

as adverse event risk factor, 24, 84

human papillomavirus infection risk, 505–506

Alterations in brain development. SeeBiological mechanisms, pathophysiologies, and susceptibilities with the potential to contribute to adverse events

Alum, 59

American Academy of Family Physicians, 437, 530

American Academy of Pediatrics, 437, 530

Amyotrophic lateral sclerosis

definition, 635

human papillomavirus vaccine and, 513–515

mechanism(s) that may contribute to symptoms of, 514

Anaphylaxis

causes, 65, 66, 632

complement-mediated, 65–66

definition, 635

DTaP vaccine and, 563–565, 587t

hepatitis A vaccine and, 428–429, 431t

hepatitis B vaccine and, 18, 20t, 468–469, 492t

human papillomavirus vaccine and, 21t, 515–516, 521t

immunoglobulin E-mediated hypersensitivity in, 64–65

influenza vaccine and, 18, 20t, 341–345, 403t

limitations of data sources, 631–632

mechanism(s) that may contribute to symptoms of, 64–66

meningococcal vaccine and, 18, 20t,608–610, 611t

MMR vaccine and, 18, 20t, 169–174, 219t, 631–632

recognized risks, 28

susceptibility to, 83–84

tetanus toxoid vaccine and, 18, 20t, 565, 587t

varicella zoster vaccine and, 18, 20t, 275–278, 284t

Animal models

application of evidence from, 89–91

contribution to the weight of mechanistic evidence, 14, 45, 47

disease processes affecting the brain, 86

influenza vaccine and Guillain-Barré syndrome, 333–334

MMR vaccine and hearing loss, 153

Antibodies and autoantibodies. See Biological mechanisms, pathophysiologies, and susceptibilities with the potential to contribute to adverse events

Antigen persistence. See Biological mechanisms, pathophysiologies, and susceptibilities with the potential to contribute to adverse events

Antigen-presenting cells, 58, 59

Antigenic drift, 293

Antigenic shift, 293

Arthralgia

chronic, in women, MMR vaccine and, 190–195, 220t

definition, 635

mechanism(s) that may contribute to symptoms of, 181, 185, 194, 517

transient, human papillomavirus vaccine and, 516–517, 521t

transient, in children, MMR vaccine and, 18, 21t, 182–190, 220t

transient, in women, MMR vaccine and, 18, 21t, 174–181, 219t

Arthritis, chronic

definition, 635

mechanism(s) that may contribute to symptoms of, 198

in women, MMR vaccine and, 195–199, 220t

Arthritis, juvenile idiopathic

definition, 641

hepatitis B vaccine and, 485–488, 493t

mechanism(s) that may contribute to symptoms of, 488

MMR vaccine and, transient arthralgia in children, 184



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement